Hidradenitis suppurativa: The role of immune dysregulation

International Journal of Dermatology

Volumn 53, Issue 10, 2014, Pages 1186-1196

  Kelly, Genevieve ^a   Sweeney, Cheryl M ^a   Tobin, Anne Marie ^b   Kirby, Brian ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b ADELAIDE AND MEATH HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERMEDIN; CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA SECRETASE; GELATINASE A; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 12; INTERLEUKIN 16; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 20; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 24; INTERLEUKIN 26; INTERLEUKIN 4; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; NICASTRIN; NOTCH1 RECEPTOR; POLYPEPTIDE ANTIBIOTIC AGENT; PRESENILIN 1; PRESENILIN 2; RANTES; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; DEFENSIN; INTERLEUKIN DERIVATIVE;

B LYMPHOCYTE; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; GENE MUTATION; GENETICS; HAIR FOLLICLE; HUMAN; IMMUNE DYSREGULATION; INHERITANCE; KERATINOCYTE; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; REVIEW; SIGNAL TRANSDUCTION; SUPPURATIVE HIDRADENITIS; T LYMPHOCYTE; COMPLICATION; IMMUNOLOGY; IMMUNOPATHOLOGY;

DEFENSINS; HIDRADENITIS SUPPURATIVA; HUMANS; IMMUNE SYSTEM DISEASES; INTERLEUKINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84907816402     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/ijd.12550     Document Type: Review

References (70)

1. Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol 2009; 60: 539-561, quiz 62-63.
2. Revuz JE, Canoui-Poitrine F, Wolkenstein P, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol 2008; 59: 596-601.
3. Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol 1996; 35: 191-194.
4. Cosmatos I, Matcho A, Weinstein R, et al. Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J Am Acad Dermatol 2013; 68: 412-419.
5. Matusiak L, Bieniek A, Szepietowski JC. Soluble interleukin-2 receptor serum level is a useful marker of hidradenitis suppurativa clinical staging. Biomarkers 2009; 14: 432-437.
6. Wolkenstein P, Loundou A, Barrau K, et al. Quality of Life Group of the French Society of D. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol 2007; 56: 621-623.
7. Esmann S, Jemec GB. Psychosocial impact of hidradenitis suppurativa: a qualitative study. Acta Derm Venereol 2011; 91: 328-332.
8. Matusiak L, Bieniek A, Szepietowski JC. Psychophysical aspects of hidradenitis suppurativa. Acta Derm Venereol 2010; 90: 264-268.
9. Matusiak L, Bieniek A, Szepietowski JC. Hidradenitis suppurativa markedly decreases quality of life and professional activity. J Am Acad Dermatol 2010; 62: 706-708, 8 e1.
10. von der Werth JM, Jemec GB. Morbidity in patients with hidradenitis suppurativa. Br J Dermatol 2001; 144: 809-813.
11. Onderdijk AJ, van der Zee HH, Esmann S, et al. Depression in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2013; 27: 473-478.
12. Nazary M, van der Zee HH, Prens EP, et al. Pathogenesis and pharmacotherapy of hidradenitis suppurativa. Eur J Pharmacol 2011; 672: 1-8.
13. Yu CC, Cook MG. Hidradenitis suppurativa: a disease of follicular epithelium, rather than apocrine glands. Br J Dermatol 1990; 122: 763-769.
14. Attanoos RL, Appleton MA, Douglas-Jones AG. The pathogenesis of hidradenitis suppurativa: a closer look at apocrine and apoeccrine glands. Br J Dermatol 1995; 133: 254-258.
15. von Laffert M, Helmbold P, Wohlrab J, et al. Hidradenitis suppurativa (acne inversa): early inflammatory events at terminal follicles and at interfollicular epidermis. Exp Dermatol 2010; 19: 533-537.
16. von Laffert M, Stadie V, Wohlrab J, et al. Hidradenitis suppurativa/acne inversa: bilocated epithelial hyperplasia with very different sequelae. Br J Dermatol 2011; 164: 367-371.
17. Fitzsimmons JS, Guilbert PR, Fitzsimmons EM. Evidence of genetic factors in hidradenitis suppurativa. Br J Dermatol 1985; 113: 1-8.
18. Von Der Werth JM, Williams HC, Raeburn JA. The clinical genetics of hidradenitis suppurativa revisited. Br J Dermatol 2000; 142: 947-953.
19. Gao M, Wang PG, Cui Y, et al. Inversa acne (hidradenitis suppurativa): a case report and identification of the locus at chromosome 1p21.1-1q25.3. J Invest Dermatol 2006; 126: 1302-1306.
20. Wang B, Yang W, Wen W, et al. Gamma-secretase gene mutations in familial acne inversa. Science 2010; 330: 1065.
21. Pan Y, Lin MH, Tian X, et al. Gamma-secretase functions through Notch signaling to maintain skin appendages but is not required for their patterning or initial morphogenesis. Dev Cell 2004; 7: 731-743.
22. Ingram JR. The aetiology of acne inversa: an evolving story. Br J Dermatol 2011; 165: 231-232.
23. Pink AE, Simpson MA, Brice GW, et al. PSENEN and NCSTN mutations in familial hidradenitis suppurativa (acne inversa). J Invest Dermatol 2011; 131: 1568-1570.
24. Pink AE, Simpson MA, Desai N, et al. Mutations in the gamma-secretase genes NCSTN, PSENEN, and PSEN1 underlie rare forms of hidradenitis suppurativa (acne inversa). J Invest Dermatol 2012; 132: 2459-2461.
25. Dvorak VC, Root RK, MacGregor RR. Host-defense mechanisms in hidradenitis suppurativa. Arch Dermatol 1977; 113: 450-453.
26. O'Loughlin S, Woods R, Kirke PN, et al. Hidradenitis suppurativa. Glucose tolerance, clinical, microbiologic, and immunologic features and HLA frequencies in 27 patients. Arch Dermatol 1988; 124: 1043-1046.
27. Lapins J, Asman B, Gustafsson A, et al. Neutrophil-related host response in hidradenitis suppurativa: a pilot study in patients with inactive disease. Acta Derm Venereol 2001; 81: 96-99.
28. van der Zee HH, van der Woude CJ, Florencia EF, et al. Hidradenitis suppurativa and inflammatory boweldisease: are they associated? Results of a pilot study. Br J Dermatol 2010; 162: 195-197.
29. Hsiao JL, Antaya RJ, Berger T, et al. Hidradenitis suppurativa and concomitant pyoderma gangrenosum: a case series and literature review. Arch Dermatol 2010; 146: 1265-1270.
30. Martinez F, Nos P, Benlloch S, et al. Hidradenitis suppurativa and Crohns disease: response to treatment with infliximab. Inflamm Bowel Dis 2001; 7: 323-326.
31. Grant A, Gonzalez T, Montgomery MO, et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol 2010; 62: 205-217.
32. Miller I, Lynggaard CD, Lophaven S, et al. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. Br J Dermatol 2011; 165: 391-398.
33. Adams DR, Yankura JA, Fogelberg AC, et al. Treatment of hidradenitis suppurativa with etanercept injection. Arch Dermatol 2010; 146: 501-504.
34. Gulliver WP, Jemec GB, Baker KA. Experience with ustekinumab for the treatment of moderate to severe Hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2012; 26: 911-914.
35. OShea JJ, Ma A, Lipsky P. Cytokines and autoimmunity. Nat Rev Immunol 2002; 2: 37-45.
36. Sweeney CM, Tobin AM, Kirby B. Innate immunity in the pathogenesis of psoriasis. Arch Dermatol Res 2011; 303: 691-705.
37. van der Zee HH, de Ruiter L, van den Broecke DG, et al. Elevated levels of tumour necrosis factor (TNF)-alpha, interleukin (IL)-1beta and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-alpha and IL-1beta. Br J Dermatol 2011; 164: 1292-1298.
38. Wolk K, Warszawska K, Hoeflich C, et al. Deficiency of IL-22 contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne inversa. J Immunol 2011; 186: 1228-1239.
39. Emelianov VU, Bechara FG, Glaser R, et al. Immunohistological pointers to a possible role for excessive cathelicidin (LL-37) expression by apocrine sweat glands in the pathogenesis of hidradenitis suppurativa/acne inversa. Br J Dermatol 2012; 166: 1023-1034.
40. Mozeika E, Pilmane M, Nurnberg BM, et al. Tumour necrosis factor-alpha and matrix metalloproteinase-2 are expressed strongly in hidradenitis suppurativa. Acta Derm Venereol 2013; 93: 301-304.
41. Matusiak L, Bieniek A, Szepietowski JC. Increased serum tumour necrosis factor-alpha in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor-alpha agents? Acta Derm Venereol 2009; 89: 601-603.
42. Giamarellos-Bourboulis EJ, Antonopoulou A, Petropoulou C, et al. Altered innate and adaptive immune responses in patients with hidradenitis suppurativa. Br J Dermatol 2007; 156: 51-56.
43. van der Zee HH, Laman JD, de Ruiter L, et al. Adalimumab (antitumour necrosis factor-alpha) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study. Br J Dermatol 2012; 166: 298-305.
44. Dreno B, Khammari A, Brocard A, et al. Hidradenitis suppurativa: the role of deficient cutaneous innate immunity. Arch Dermatol 2012; 148: 182-186.
45. Sutton C, Brereton C, Keogh B, et al. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J Exp Med 2006; 203: 1685-1691.
46. Schroder K, Tschopp J. The inflammasomes. Cell 2010; 140: 821-832.
47. van der Zee HH, Laman JD, Boer J, et al. Hidradenitis suppurativa: viewpoint on clinical phenotyping, pathogenesis and novel treatments. Exp Dermatol 2012; 21: 735-739.
48. Saraiva M, OGarra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol 2010; 10: 170-181.
49. Moore KW, de Waal Malefyt R, Coffman RL, et al. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19: 683-765.
50. Wilke CM, Wang L, Wei S, et al. Endogenous interleukin-10 constrains Th17 cells in patients with inflammatory bowel disease. J Transl Med 2011; 9: 217.
51. Maddur MS, Miossec P, Kaveri SV, et al. Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. Am J Pathol 2012; 181: 8-18.
52. Liang SC, Tan XY, Luxenberg DP, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006; 203: 2271-2279.
53. Schlapbach C, Hanni T, Yawalkar N, et al. Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol 2011; 65: 790-798.
54. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3: 133-146.
55. Park H, Li Z, Yang XO, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005; 6: 1133-1141.
56. Cua DJ, Sherlock J, Chen Y, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003; 421: 744-748.
57. Guenova E, Teske A, Fehrenbacher B, et al. Interleukin expression in pyoderma gangrenosum and targeted therapy with ustekinumab. Arch Dermatol 2011; 147: 1203-1205.
58. Rutz S, Eidenschenk C, Ouyang W. IL-22, not simply a Th17 cytokine. Immunol Rev 2013; 252: 116-132.
59. Kishimoto T. Interleukin-6: from basic science to medicine-40 years in immunology. Annu Rev Immunol 2005; 23: 1-21.
60. Tanaka T, Kishimoto T. Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases. Int J Biol Sci 2012; 8: 1227-1236.
61. Hofmann SC, Saborowski V, Lange S, et al. Expression of innate defense antimicrobial peptides in hidradenitis suppurativa. J Am Acad Dermatol 2012; 66: 966-974.
62. Schlapbach C, Yawalkar N, Hunger RE. Human beta-defensin-2 and psoriasin are overexpressed in lesions of acne inversa. J Am Acad Dermatol 2009; 61: 58-65.
63. Harder J, Schroder JM. Antimicrobial peptides in human skin. Chem Immunol Allergy 2005; 86: 22-41.
64. Semple F, Webb S, Li HN, et al. Human beta-defensin 3 has immunosuppressive activity in vitro and in vivo. Eur J Immunol 2010; 40: 1073-1078.
65. Boer J, Weltevreden EF. Hidradenitis suppurativa or acne inversa. A clinicopathological study of early lesions. Br J Dermatol 1996; 135: 721-725.
66. van der Zee HH, de Ruiter L, Boer J, et al. Alterations in leucocyte subsets and histomorphology in normal-appearing perilesional skin and early and chronic hidradenitis suppurativa lesions. Br J Dermatol 2012; 166: 98-106.
67. Hunger RE, Surovy AM, Hassan AS, et al. Toll-like receptor 2 is highly expressed in lesions of acne inversa and colocalizes with C-type lectin receptor. Br J Dermatol 2008; 158: 691-697.
68. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124: 783-801.
69. Melnik BC, Plewig G. Impaired Notch signalling: the unifying mechanism explaining the pathogenesis of acne inversa. Br J Dermatol 2013; 168: 876-878.
70. Gentle ME, Rose A, Bugeon L, et al. Noncanonical Notch signaling modulates cytokine responses of dendritic cells to inflammatory stimuli. J Immunol 2012; 189: 1274-1284.